4D Molecular Therapeutics Grants 124,200 RSUs to Nine New Hires
4D Molecular Therapeutics granted 124,200 restricted stock units to nine new non-executive employees on February 10, 2026 under its 2025 Employment Inducement Award Plan. The compensation committee approved the grants under Nasdaq Rule 5635(c)(4), which could marginally increase dilution for existing shareholders.
1. Inducement RSU Grants
The compensation committee of 4D Molecular Therapeutics approved the grant of 124,200 restricted stock units to nine new non-executive employees on February 10, 2026 as inducement grants. These awards aim to secure specialized talent as the company advances its late-stage therapeutic candidates.
2. Employment Inducement Award Plan
The grants were issued under the Company’s 2025 Employment Inducement Award Plan, as amended, leveraging Nasdaq Rule 5635(c)(4) to permit equity awards outside existing share reserves. While designed to attract key hires, the awards will modestly dilute existing shareholders.